Primary malignant melanoma of the female urethra: a rare case of cytological observation

Naomi Kawaguchi1, Kyoko Nambu1, Asuka Sekiya1, Toshimasa Sakakima2, Masashi Matsuyama1, Fumimasa Etori1, Hisao Komeda3, Kuniaki Hirai1, Naoki Watanabe1, Takafumi Naiki2, Tetsuya Yamada4 and Takuji Tanaka1,5*

Abstract
We herein report a rare case of primary malignant urethral melanoma developed in an elderly Japanese patient with hypertension, diabetes and hyperlipidemia. An 80-year-old female presented at our hospital with a history of urodynia and perineal pain lasting for several months. Cystoscopy revealed cystitis and urethritis with erosion. At that time, urinary cytology was negative for malignancy, although melanophages were observed. Four months later, lower abdominal computed tomography and magnetic resonance imaging indicated urethral tumors. Urinary cytology subsequently detected malignant melanoma, and a biopsy of the urethra confirmed malignancy. Although inguinal lymph node metastasis was found 16 months postoperatively, the patient has remained free of disease for more than six years after surgery and chemotherapy.

Keywords: Malignant melanoma, urethra, female, urinary cytology, immunohistochemistry

Introduction
Primary melanoma of the genitourinary tract is rare, accounting for less than 1% of all cases of melanoma [1,2], while primary malignant melanoma of the urethra in females represents only 0.2% of all malignant melanomas [3]. Since the clinical presentation of urethral melanoma is similar to that of urothelial carcinoma, there is frequently a delay in diagnosis [4]. According to the literature, most cases of malignant melanoma in the female urethra involve the meatus and/or distal urethra [5]. Common clinical signs include bleeding, discharge, voiding dysfunction and the presence of tumorous masses [6]. Clinical misdiagnosis and delayed diagnosis of urethral melanomas result in a poor prognosis [6]. In this report, we present a case of malignant melanoma originating from the urethra in an elderly Japanese female and discuss the cytological and immunohistochemical findings.

Case report
On November 16, 2009, an 80-year-old female presented to our hospital with urodynia and perineal pain lasting for several months. She had no history of urogenital symptoms or diseases, although she had hypertension, hyperlipidemia and diabetes. At presentation, the results of a chest X-ray and routine serum biochemistry tests were normal, with the exception of the levels of lactate dehydrogenase (230 IU/L), blood urine nitrogen (25.7 mg/dl) and creatinine (0.84 mg/dl). A urinalysis showed cloudiness of the urine with macrophages containing brown granular pigments [7] (Figure 1a). Urinary cytology (conventional smears) was negative; however, a few macrophages containing brown granules were noted (Figure 1b). A cystoscopic examination showed necrotic and edematous mucosa in the trigone of the urinary bladder, bladder neck and urethra. The patient was diagnosed with non-specific cystitis and given antibiotics. Her symptoms disappeared; however, the findings of cystoscopy did not improve. Lower abdominal computed tomography (CT) showed slight thickening of the lower wall of the urinary bladder (Figure 2), while magnetic resonance imaging (MRI) detected flat elevation (4 cm in width) at the internal ostium of the urethra (Figure 3). Three months later, urinary cytology disclosed the presence of atypical...
cells containing brown pigments suggestive of malignant melanoma (Figure 4), and a pathological examination of biopsy specimens of the bladder (obtained via transurethral resection) and urethra revealed malignant melanoma of the urethra (Figures 5a and 5b). Melanin pigments were detected according to the Fontana-Masson technique (Figure 5c). In addition, the superficial lymph nodes were palpable; however, no findings suggestive of metastasis were found on an abdominal examination.

The patient underwent extensive surgery, including cystourethrectomy, vaginectomy, vulvectomy and regional lymph node dissection. A gross examination of the resected specimen revealed black lesions in the urethra and bladder neck (Figure 6), and a microscopic examination demonstrated infiltration of pigmented tumors cells around the urethral epithelium (Figure 7a). The tumor cells were large epithelioids with dusty black melanin pigments and frequent mitotic figures (Figure 7b). Immunohistochemistry showed the malignant cells to be immunoreactive for HMB-45 (Figure 7c) and S-100 protein (Figure 7d). A macroscopically clean surgical margin was obtained, and subsequent histology revealed a microscopic negative margin. In addition, there was no evidence of any other primary tumors, including skin melanoma. Based on these findings, we diagnosed the patient with primary malignant melanoma of the urethra. Although she received chemotherapy [DAV therapy: DTIC (dacarbazine), ACNU (nimustine) and VCR (vincristine)], 16 months after the surgery, metastasis was detected in the right inguinal lymph nodes, which were consequently removed. The patient is currently under close follow-up every four months. She has experienced no episodes of recurrence of melanoma, including systemic metastasis, for more than six years, as assessed on chest, abdominal and pelvic computed tomography.

Discussion
Malignant melanoma originates from melanoblasts differentiated from neuroectoderm neural crest cells. Neural crest cells differentiate to melanocytes in the skin, oral mucosa, nasal mucosa and vulva; therefore, malignant melanoma occurs in these regions. Most malignant melanomas develop in the skin, accounting for 81% of all cases of melanoma. In contrast, the rate of malignant mucosal melanomas is 17%, and these lesions mostly develop in the eyelid and eyeball. We previously reported a case of primary malignant melanoma in the urinary bladder [8]. In addition, a case of simple melanosis of the urinary bladder was recently reported [9]; this rare condition is occasionally associated with malignant melanoma.

Malignant urethral melanomas, which usually originate from the distal urethra [3], account for 0.2% of all malignant melanomas and 4% of all urethral cancers [5]. The first case of malignant urethral melanoma was reported by Tyrell and Reed more than 100 years ago [6,10]. Malignant urethral melanoma is three times as common in females as in males and is more frequent in the Caucasian population. Most cases are

![Figure 1](image1.png)

**Figure 1.** Urinalysis and urinary cytology (conventional smear). (a) Macrophages containing brown granular pigments (melanophages) in the urinary sediment upon presentation of the patient in our hospital. (b) Melanophages in the urinary cytology assessed upon presentation of the patient to our hospital. Original magnification, (a) and (b): x400.

![Figure 2](image2.png)

**Figure 2.** CT shows slight thickening (arrow) of the lower wall of the urinary bladder.
masses, hematuria and dysuria with a decreased urinary stream [13]. Although urethral melanomas are typically polypoid [11], our case was not. Since one-fifth of primary malignant urethral melanomas are amelanotic [11], physicians should carefully differentiate primary neoplasms involving the urethra.

In the present case, we suspected urogenital malignant melanoma upon presentation of the patient to our hospital, based on the presence of melanophages in the urinalysis and urinary cytology. Three months later urethral malignant melanoma was confirmed by urinary cytology and other examinations, suggesting that the cytological method helped us to make our final diagnosis.
Microscopic examinations of malignant urethral melanomas demonstrate a wide histologic spectrum of patterns, including diffuse, nested, fascicular, and storiform growth of pleomorphic cells [6]. Immunohistochemistry of melanocyte differentiation is therefore required to obtain an accurate diagnosis of this malignancy. The most frequently used melanocytic markers are S-100 protein and HMB-45. Monoclonal antibodies against S-100 protein react with more than 90% of melanomas [14]. However, although HMB-45 is quite specific for melanocytic neoplasms, it is less sensitive than S-100 protein for diagnosing melanoma [14]. In the present case, strong immunoreactivity against HMB-45 was conclusively positive in the melanoma cells, whereas the positive reaction to S-100 protein was weak. These findings are similar to those observed in our previous case of malignant urinary bladder melanoma [8], thus suggesting the utility of measuring the HMB-45 antibody titer for immunohistochemically detecting malignant urogenital melanomas.

Malignant urethral melanomas have a worse prognosis than malignant cutaneous melanomas, as lymph node metastasis is usually found at the time of the initial diagnosis and there is a significant delay in diagnosis in such cases [10]. Malignant urethral melanomas frequently present as polypoid tumors and are mistaken for other malignant diseases and even benign lesions, including urethral polyps, caruncles, mucosal prolapse or chancre [6,15]. Macroscopically, the present case did not involve a polypoid tumor, but rather an elevated lesion that was black in color. Primary malignant urethral melanomas in females tend to metastasize to adjacent areas at an early stage, including the regional lymph nodes and occasionally distant sites via the hematogenous route [16]. In this case, we found inguinal lymph node metastasis 16 months after surgery. However, no further recurrence was noted following resection of the metastatic lymph nodes, although recurrence of urethral melanoma has been reported to occur within 12.5 months [12].

Although the optimum treatment for urethral melanomas in females has not yet been defined, our chemotherapy regimen (DAV therapy) for malignant cutaneous melanoma [17] was effective in this case. Radical surgical resection with postoperative adjuvant chemotherapy or immunotherapy is also recommended. However, there is little clinical experience to support the use of such adjuvant treatment.

In conclusion, we herein reported a case of malignant urethral melanoma in an 80-year-old Japanese female with cytological and immunohistochemical findings that were helpful for making an early and accurate diagnosis of malignant melanoma in the urogenital region.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions

<table>
<thead>
<tr>
<th>Authors’ contributions</th>
<th>NK</th>
<th>KH</th>
<th>AS</th>
<th>TS</th>
<th>MM</th>
<th>FE</th>
<th>KH</th>
<th>NW</th>
<th>TN</th>
<th>TY</th>
<th>TT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research concept and design</td>
<td>✓</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>✓</td>
<td>✓</td>
<td>--</td>
<td>--</td>
<td>✓</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Collection and/or assembly of data</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Data analysis and interpretation</td>
<td>✓</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>✓</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Writing the article</td>
<td>✓</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>✓</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Critical revision of the article</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>✓</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Final approval of article</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Statistical analysis</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

Figure 6. Macroscopic view of the resected urinary bladder and urethra. Note the black urethral mucosa.

Figure 7. Histopathology of malignant melanoma of the urethra. (a) Malignant melanoma cells proliferating around the urethra. (b) Large melanoma cells containing melanin are seen. The tumor cells were strongly immunoreactive for (c) HMB-45 and weakly immunoreactive for (d) S-100 protein. (a) and (b) H & E stain. (c) HMG-45 immunohistochemistry. (d) S-100 immunohistochemistry. Original magnifications (a) x40, (b) x400, (c) x400 and (d) x200.
References


Acknowledgement
This work was partly supported by a Grant-in-Aid for the 3rd Terms Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare of Japan.

Publication history
Editors: Anna Nasierowska-Guttmejer, Clinical Hospital of Ministry of Internal Affairs, Poland.
Jianyu Rao, UCLA Ronald Reagan Medical Center, USA.
Esther Diana Rossi, Catholic University of Sacred Heart, Italy.
Received: 17-Jun-2014 Final Revised: 25-Jul-2014
Accepted: 08-Aug-2014 Published: 20-Aug-2014

Citation: